Everything A Value Investor Could Want: La Jolla Pharmaceutical Company (LJPC), Verastem, Inc. (VSTM)

TANG KEVIN C, Director, bought 79,214 shares of the La Jolla Pharmaceutical Company (NASDAQ:LJPC) in an exchange that happened on January 9th. The stock was bought at an average price of $5.54 per share, amounting to a transaction worth $438,806. The purchase was made public in a document filed with the SEC. Additionally, Chief Scientific Officer Rolke James bought 1,600 shares of this stock in a transaction that took place on January 9th. The stock was bought at an average price of $6.09 per share, for a total exchange amounting to $9,746. After the transaction, the Chief Scientific Officer Rolke James currently holds 76,330 shares of the company’s stock, which is worth approximately $465613.

With this stock price’s latest movement, it is now -85.25% away from its 1-year high and 21.76% higher than its 1-year low price. In the past seven days, the stock price volatility for La Jolla Pharmaceutical Company was 29.16%, whereas its volatility in the past 30 days has been 13.26%. This public company’s stock also has a beta score of 1.79. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) most recently published its quarterly earnings results. The firm posted -$1.93 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of -$2.01 by $0.08. The publicly-traded organization reported revenue of $3.47 million for the quarter, compared to the average analyst forecast calling for $3.40 million, which was surpassing the analyst consensus estimate.

Shares of La Jolla Pharmaceutical Company (LJPC) surged 0.16%, amounting to a gain of $0.0099999999999998 per share, to finish the regular trading session at $6.10 on Thursday 01/10/2019. After beginning the session at $6.39, shares of La Jolla Pharmaceutical Company reached as high as $6.41 during the day, while hitting a 1-day low of $5.75. Trade volume reached 2,635,049 shares against this stock’s average daily volume of 748.44K shares, with a total float of 24.85M. As a consequence of the price increase, La Jolla Pharmaceutical Company now has a current market value of 151.95M.

Verastem, Inc. (NASDAQ:VSTM) subtracted -0.98% to its trading price by the close of the most recent session, dropping from its previous closing price of $4.09 to $4.05. This stock decreased in value by 15.38% during the last 7-day period, and experienced a gain of -9.19% over the past 30-day period. In the past three months, this stock’s price lost by -40.96% , and subtracted -48.34% to its price during the last six months of trading. VSTM demonstrated a yearly price gain of 37.76% , while its year-to-date (YTD) price performance has been up 20.54% . This stock’s price changed by +28.98% compared to its 90-day low, and moved down -36.92% comparing to its 90-day high price.

Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the VSTM stock as “Sell”. In the short-term, Verastem, Inc. (VSTM) has a 20-day average volume of 2,863,450 shares and short-term indicators sets the VSTM stock as “ 40% Buy ” on average basis. In the medium-term, VSTM stock has a 50-Day average volume of 2,320,288 shares and medium-term indicators gave the average rating of “ 25% Sell ”, while in the long-term period the FB stock has a 100-Day average volume of 2,858,676 shares. On average, long-term indicators rated the stock as “67% Sell ”. The overall picture from all short, medium and long-term indicators sets the VSTM stock as “16% Sell ” on average basis.

Recently, multiple brokerages have sent out reports on VSTM. BTIG Research, for example, Initiated its rating on shares of Verastem, Inc. to a “Buy”, while setting a $17 price target on shares of the company’s stock, according to a research note from Friday July 13th, 2018. Seaport Global Securities Initiated their target price for this stock to $14, while giving the stock a “Buy” rating, as stated in a research report from Wednesday, May 2nd, 2018. B. Riley FBR, Inc., on the other hand, Initiated a “Buy” rating on this stock, while posting a $15 price target on shares of this company’s stock in a research note dated Thursday, March 8th, 2018.

In other news related to Verastem, Inc. stock, 50.63% shares of VSTM held by institutions. The total number of institutions who held the VSTM shares was 142, according to most recent SEC filling. During the past quarter, total 37,361,969 shares held by institutions with the net change of 4,920,081 shares. In the meantime, 39 new institutions bought the shares of Verastem, Inc. for the first time and 23 institutions sold all their holdings in the company’s common stock. 98 institutions increased their investment in the VSTM stock and 40 institutions decreased their investment in the Verastem, Inc. (VSTM)’s stock during the last quarter.